Lenselink Charlotte H, Melchers Willem J G, Quint Wim G V, Hoebers Annelies M J, Hendriks Jan C M, Massuger Leon F A G, Bekkers Ruud L M
Department of Obstetrics and Gynaecology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
PLoS One. 2008;3(11):e3743. doi: 10.1371/journal.pone.0003743. Epub 2008 Nov 17.
Infection with Human Papillomavirus (HPV) is a necessary event in the multi-step process of cervical carcinogenesis. Little is known about the natural history of HPV infection among unscreened young adults. As prophylactic vaccines are being developed to prevent specifically HPV 16 and 18 infections, shifts in prevalence in the post vaccine era may be expected. This study provides a unique opportunity to gather baseline data before changes by nationwide vaccination occur.
This cross-sectional study is part of a large prospective epidemiologic study performed among 2065 unscreened women aged 18 to 29 years. Women returned a self-collected cervico-vaginal specimen and filled out a questionnaire. All HPV DNA-positive samples (by SPF(10) DEIA) were genotyped using the INNO-LiPA HPV genotyping assay. HPV point prevalence in this sample was 19%. Low and high risk HPV prevalence was 9.1% and 11.8%, respectively. A single HPV-type was detected in 14.9% of all women, while multiple types were found in 4.1%. HPV-types 16 (2.8%) and 18 (1.4%) were found concomitantly in only 3 women (0.1%). There was an increase in HPV prevalence till 22 years. Multivariate analysis showed that number of lifetime sexual partners was the most powerful predictor of HPV positivity, followed by type of relationship, frequency of sexual contact, age, and number of sexual partners over the past 6 months.
This study shows that factors independently associated with HPV prevalence are mainly related to sexual behaviour. Combination of these results with the relative low prevalence of HPV 16 and/or 18 may be promising for expanding the future target group for catch up vaccination. Furthermore, these results provide a basis for research on possible future shifts in HPV genotype prevalence, and enable a better estimate of the effect of HPV 16-18 vaccination on cervical cancer incidence.
人乳头瘤病毒(HPV)感染是子宫颈癌多步骤致癌过程中的必要事件。对于未接受筛查的年轻成年人中HPV感染的自然史知之甚少。由于正在研发预防性疫苗以特异性预防HPV 16和18感染,预计疫苗接种后患病率会发生变化。本研究提供了一个独特的机会,可在全国范围接种疫苗引发变化之前收集基线数据。
这项横断面研究是一项大型前瞻性流行病学研究的一部分,该研究针对2065名年龄在18至29岁之间未接受筛查的女性开展。女性返回自行采集的宫颈阴道样本并填写问卷。所有HPV DNA阳性样本(通过SPF(10) DEIA法检测)均使用INNO-LiPA HPV基因分型检测法进行基因分型。该样本中HPV的现患率为19%。低风险和高风险HPV的现患率分别为9.1%和11.8%。在所有女性中,14.9%检测到单一HPV型别,而4.1%检测到多种型别。仅在3名女性(0.1%)中同时发现HPV 16型(2.8%)和18型(1.4%)。HPV患病率在22岁之前呈上升趋势。多变量分析显示,性伴侣数量是HPV阳性最有力的预测因素,其次是性关系类型、性接触频率、年龄以及过去6个月内的性伴侣数量。
本研究表明,与HPV患病率独立相关的因素主要与性行为有关。将这些结果与HPV 16和/或18相对较低的患病率相结合,可能有助于扩大未来补种疫苗的目标人群。此外,这些结果为研究未来HPV基因型患病率可能发生的变化提供了依据,并能更好地评估HPV 16 - 18疫苗接种对子宫颈癌发病率的影响。